National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients

A prospective, open label phase 2 clinical trial assessing safety, complications and feasibility of radical prostatectomy (RARP) plus local stereotactic body radiotherapy (SBRT) to bone metastases in combination with short-term medical castration to a select population of prostate cancer patients with oligometastatic disease.

Trial Details

NCT ID
NCT04086290
Phase
PHASE1 / PHASE2
Sponsor
Peter Busch Østergren
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • RARP
  • SBRT
  • ADT
Locations (sample)
  • Herlev, Denmark|55.72366,12.43998

Key Eligibility Criteria

  • Age 18 years or older and willing and able to provide informed consent;
  • Stage cT1 ≤ cT3b, Clinical resectable
  • Gleason score ≥ 6
  • ≤ 3 bone metastases localized to the spine, pelvis or humeral/femoral bones as evaluated by 68Ga-PSMA PET/CT and magnetic resonance imaging (MRi)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →